In this presentation, Anand A. Patel, MD, reviewed the contemporary standard-of-care treatment roadmap for AML in 2025, covering key phases like induction chemotherapy (eg, the “7+3” regimen), consolidation…
Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, New York, discusses the treatment strategies for patients who develop secondary acute myeloid leukemia (AML) following hypomethylating agent…
Multiple clinical trials are currently underway examining the possible synergistic effects of combining chemotherapy with immunotherapies for patients with bladder cancer and other metastases.
Bacillus Calmette-Guérin (BCG) is an effective biologic therapy widely used in patients with non-muscle invasive bladder cancer. Sanofi recently announced their intent to discontinue BCG production, leaving Merck…
Julio A. Aguirre-Ghiso, PhD, Professor of Medicine, Hematology, and Medical Oncology at the Tisch Cancer Institute Icahn School of Medicine at Mount Sinai, is leading a study on…
Neural networks (a.k.a. deep learning algorithms) can be used to teach computers to distinguish various types of disease via prior analysis of massive amounts of clinical data.
Immunotherapy with newly developed “immune checkpoint inhibitors” has led to striking advances in treatment for aggressive malignancies such as melanoma, non-small cell lung cancer, and renal cell carcinoma.…
New research is helping scientists better understand gene modification’s effects on many forms of bladder cancer. Additionally, results from numerous recent studies seem to foreshadow a change of…
